BRIEF--Lilly links up with Eva to bring Olumiant to Africa

US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030.

Discovered by Incyte and licensed to Lilly, Olumiant is for the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis and COVID-19.

Ilya Yuffa, executive vice president and president of Lilly, said: “Our commitment to expanding access to affordable and innovative medicines for people living in low- to middle-income countries continues.